Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis

Gao, Shen; Shen, Jing; Mukku, Venkata Kishore; Wang, Mei Jia; Akhtar, Muzina; Liu, Wei

doi:10.1177/0003319715611826

Cited by 6 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of trials using PEB for the treatment of BMS or DES ISR showed a significant reduction in the risk of occurrence of MACE (P<0.001), TLR (P=0.006), and the recurrence of binary in-segment restenosis (P<0.001) in the group with PEB compared with an inhomogeneous control group (POBA, PES). 22 Similarly, Gao et al 23 found that the treatment of ISR with PEB significantly reduced MACE (P<0.01), death (P=0.04), TLR (P<0.01), and LLL (P<0.01) compared with POBA; however, the differences were not significant when compared with DES (PES/EES).…”

Section: Resultsmentioning

confidence: 91%

Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis

Pleva

Kukla

Kušnierová

et al. 2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

In contrast, drug-eluting balloon (DEB) catheters allow short-term passage of the active substance into the vascular Background-The aim of this prospective randomized noninferiority study was to compare the efficacy of paclitaxeleluting balloon (PEB) catheters and everolimus-eluting stents (EES) in the treatment of bare metal stent restenosis. Methods and Results-A total of 136 patients were enrolled in the study. Each treatment group included 68 patients with 74 in-stent restenotic lesions. The primary end point was in-segment late lumen loss (LLL) at 12 months. Secondary end points were the incidence of binary in-stent restenosis and 12-month major adverse cardiac events. The 2-sided 95% confidence interval of LLL difference between treatments (0.149-0.558) was greater than noninferiority margin (0.12), which demonstrates both noninferiority and superiority of PEB treatment. Furthermore, the PEB group had significantly less 12-month LLL than the EES group (0.02 versus 0.19 mm; P=0.0004).

show abstract

Section: Resultsmentioning

confidence: 91%

Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis

Pleva

Kukla

Kušnierová

et al. 2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…CHD is the most common cardiovascular disease, primarily due to coronary artery stenosis or obstruction caused by atherosclerosis [22] . PCI is one of the important tools for the treatment of CHD, but the consequent occurrence of restenosis severely affects the efficacy of PCI in CHD patients [23–25] . Although drug-eluting stents can reduce the incidence of restenosis in the short term, the incidence of restenosis remains high in the end.…”

Section: Discussionmentioning

confidence: 99%

The effect of Huoxue Huayu decoction on restenosis after percutaneous coronary intervention in patients with coronary heart disease

Hou

Wang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Percutaneous coronary intervention (PCI), as the most common treatment for coronary heart disease (CHD), has the advantages of simple operation, minimal invasion, rapid reconstruction, and vessels opening. The problem, however, is that many patients develop restenosis within 6 months after PCI. In traditional Chinese medicine (TCM), Huoxue Huayu decoction (HXHYD) is widely used to treat cardiovascular diseases, and its important role as a complementary and alternative therapy for the prevention and treatment of post-PCI restenosis in CHD patients has been extensively reported. However, controversy exists among different studies. Therefore, we collected relevant randomized controlled trials for a meta-analysis to assess the efficacy and safety of HXHYD in the prevention of post-PCI restenosis in patients with CHD. Methods: Randomized controlled trials of HXHYD in the prevention of post-PCI restenosis in patients with CHD will be retrieved from PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wan Fang Database, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, and Clinical Trial Register. The 2 authors will independently conduct the literature search, literature screening, data extraction, and quality assessment. Data analysis will be performed using STATA 14.0. Results: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication. Conclusion: This study will provide high-quality, evidence-based medical evidence for the efficacy and safety of HXHYD in the prevention of post-PCI restenosis in patients with CHD. Ethics and dissemination: Ethical approval is not required for this study. The systematic review will be published in a peer-reviewed journal, presented at conferences, and shared on social media platforms. This review would be disseminated in a peer-reviewed journal or conference presentations. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/PNZSM.

show abstract

“…Stent thrombosis after the treatment of ISR with DCB angioplasty is rare. 8) Although the doctor insisted that the patient take oral aspirin and clopidogrel after DCB treatment, she suffered from STEMI due to late stent stenosis. Further examinations indicated the patient might have antiplatelet resistance due to gene mutations.…”

Section: Discussionmentioning

confidence: 99%

Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis

Wang

Chen

et al. 2021

Int. Heart J.

View full text Add to dashboard Cite

A 41-year-old woman with chest pain for 6 hours was admitted to our chest pain center, presenting with acute myocardial infarction. Coronary angiography showed acute total occlusion in the proximal left anterior descending artery due to late stent thrombosis. After thrombus aspiration and intracoronary administration of 0.5 mg tirofiban, repeated angiography showed that no obvious residual stenosis remained. The patient underwent drug-coated balloon angioplasty 69 days ago and was then administered dual antiplatelet treatment (aspirin and clopidogrel) uninterruptedly. Genetic testing found that both cytochrome P450 2C19 (CYP2C19) (G681A) and glycoprotein Ia (GPIa) (C807T, G873A) were hybrid mutant types, demonstrating that the patient was possibly resistant to clopidogrel and aspirin simultaneously. Thus, clopidogrel was replaced by ticagrelor and no more cardiovascular adverse events occurred during the 2-year follow-up.

show abstract

Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis

Cited by 6 publications

References 32 publications

Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis

Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis

The effect of Huoxue Huayu decoction on restenosis after percutaneous coronary intervention in patients with coronary heart disease

Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis

Contact Info

Product

Resources

About